TFF Pharmaceuticals, Inc. (TFFP)
| Market Cap | 392.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.37M |
| Shares Out | 20.87M |
| EPS (ttm) | -2.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $19.35 |
| Previous Close | $17.67 |
| Change ($) | 1.68 |
| Change (%) | 9.51% |
| Day's Open | 17.75 |
| Day's Range | 17.60 - 21.14 |
| Day's Volume | 801,909 |
| 52-Week Range | 3.51 - 21.14 |
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals to present at H.C. Wainwright Virtual BioConnect 2021 Conference, with a corporate presentation available on January 11, 6AM ET.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces first dosing of asthma patients with Voriconazole Inhalation Powder in a Ph.1b clinical trial for the treatment of IPA.
AUSTIN, Texas--(BUSINESS WIRE)-- #Jefferies--TFF Pharmaceuticals to present at the Jefferies Virtual London Healthcare Conference, with a corporate presentation on November 19, at 2:55 PM ET.
TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q3 2020 Results - Earnings Call Transcript
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals reports third quarter 2020 financial and business results - Conference call today, Thursday, November 5, 2020 at 4:30pm ET
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals and Felix Biotechnology sign Letter of Intent for a Collaboration, Development and License Agreement for bacteriophage therapies.
AUSTIN, Texas & MENLO PARK, Calif.--(BUSINESS WIRE)--TFF Pharmaceuticals and Augmenta Bioworks enter into a worldwide joint development agreement for COVID-19 monoclonal antibody therapies.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces third quarter 2020 financial results and business update conference call on November 5, 2020.
TFF possess the rights to a game-changing drug formulation technology. They have a cost-efficient, fast route to market for their improved drugs.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces positive preclinical results with University of Georgia universal influenza vaccines.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals expands its cGMP manufacturing capabilities with Experic by installing a Thin Film Freezing processing line.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals updates progress of human clinical trial with Tacrolimus Inhalation Powder for prevention of lung transplant rejection.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces results of its 2020 Annual Meeting of Stockholders
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals comments on animal studies in the development of high potency remdesivir as a dry powder for inhalation by Thin Film Freezing.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals (NASDAQ: TFFP) announces topline results of Voriconazole Inhalation Powder Phase 1 clinical trial.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals to participate in Anti-fungal Webinar presented by Maxim Group LLC on September 17th, 2020
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) will present at the H.C.
With Wall Street set to see its best August in 36 years on coronavirus cure optimism, Fed's plan to keep rates low and upbeat consumer confidence put spotlight on stocks with best month-to-dat...
TFF Pharmaceuticals: Undervalued Novel Drug Manufacturing Technique
TFF Pharmaceuticals (NASDAQ: TFFP) shares are trading higher after the company on Thursday reported a global licensing deal with UNION therapeutics for its Thin Film Freezing technology in com...
TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q2 2020 Results - Earnings Call Transcript
HELLERUP, Denmark, Aug. 13, 2020 /PRNewswire/ -- Niclosamide identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir UNION has advanc...
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals in worldwide licensing agreement with UNION therapeutics for its Thin Film Freezing technology in combination with niclosamide.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals (NASDAQ:TFFP) reports second quarter 2020 financial and business results - Conference call today at 4:30 PM ET
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), announces $25.9 million in private financing to further advance its Thin Film Freezing technology platform.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), it will release its second quarter 2020 financial results on August 13, 2020 at 4:00 PM ET.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announces completion of dosing for Voriconazole Inhalation Powder Phase 1 clinical trial.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals Comments on Research on the Re-formulation of Remdesivir to a Dry Powder Form for COVID-19 Antiviral Treatment
TFF Pharmaceuticals' (TFFP) CEO Glenn Mattes on Q1 2020 Results - Earnings Call Transcript
About TFFP
TFF Pharmaceuticals, an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company has a research collaboration with the University of Georgia's Center for Vaccines and Immunology (CVI), along with the University of Texas at Austin (UT Austin), to evaluate the immunogenicity of universal influenza... [Read more...]
| Industry Biotechnology | IPO Date Oct 25, 2019 |
| CEO Glenn R. Mattes | Employees 4 |
| Stock Exchange NASDAQ | Ticker Symbol TFFP |
Analyst Forecasts
According to 3 analysts, the average rating for TFFP stock is "Buy." The 12-month stock price forecast is 25.67, which is an increase of 32.66% from the latest price.